Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.
Identifieur interne : 002C65 ( PubMed/Corpus ); précédent : 002C64; suivant : 002C66Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.
Auteurs : Runtao He ; Anton Adonov ; Maya Traykova-Adonova ; Jingxin Cao ; Todd Cutts ; Elsie Grudesky ; Yvon Deschambaul ; Jody Berry ; Michael Drebot ; Xuguang LiSource :
- Biochemical and biophysical research communications [ 0006-291X ] ; 2004.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Aurintricarboxylic Acid (pharmacology), Cell Division (drug effects), Chlorocebus aethiops, Dose-Response Relationship, Drug, Reproducibility of Results, SARS Virus (drug effects), SARS Virus (growth & development), SARS Virus (ultrastructure), Sensitivity and Specificity, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Vero Cells, Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Aurintricarboxylic Acid.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : Cell Division, SARS Virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- growth & development : SARS Virus.
- ultrastructure : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Drug, Reproducibility of Results, Sensitivity and Specificity, Vero Cells.
Abstract
The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs alpha and beta, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs alpha and beta, ATA was approximately 10 times more potent than IFN alpha and 100 times more than interferon beta at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.
DOI: 10.1016/j.bbrc.2004.06.076
PubMed: 15249217
Links to Exploration step
pubmed:15249217Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.</title><author><name sortKey="He, Runtao" sort="He, Runtao" uniqKey="He R" first="Runtao" last="He">Runtao He</name><affiliation><nlm:affiliation>National Microbiology Laboratory, Health Canada, 1015 Arlington St., Winnipeg, MB, Canada R3E 3R2. runtao_he@hc-sc.gc.ca</nlm:affiliation></affiliation></author><author><name sortKey="Adonov, Anton" sort="Adonov, Anton" uniqKey="Adonov A" first="Anton" last="Adonov">Anton Adonov</name></author><author><name sortKey="Traykova Adonova, Maya" sort="Traykova Adonova, Maya" uniqKey="Traykova Adonova M" first="Maya" last="Traykova-Adonova">Maya Traykova-Adonova</name></author><author><name sortKey="Cao, Jingxin" sort="Cao, Jingxin" uniqKey="Cao J" first="Jingxin" last="Cao">Jingxin Cao</name></author><author><name sortKey="Cutts, Todd" sort="Cutts, Todd" uniqKey="Cutts T" first="Todd" last="Cutts">Todd Cutts</name></author><author><name sortKey="Grudesky, Elsie" sort="Grudesky, Elsie" uniqKey="Grudesky E" first="Elsie" last="Grudesky">Elsie Grudesky</name></author><author><name sortKey="Deschambaul, Yvon" sort="Deschambaul, Yvon" uniqKey="Deschambaul Y" first="Yvon" last="Deschambaul">Yvon Deschambaul</name></author><author><name sortKey="Berry, Jody" sort="Berry, Jody" uniqKey="Berry J" first="Jody" last="Berry">Jody Berry</name></author><author><name sortKey="Drebot, Michael" sort="Drebot, Michael" uniqKey="Drebot M" first="Michael" last="Drebot">Michael Drebot</name></author><author><name sortKey="Li, Xuguang" sort="Li, Xuguang" uniqKey="Li X" first="Xuguang" last="Li">Xuguang Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15249217</idno><idno type="pmid">15249217</idno><idno type="doi">10.1016/j.bbrc.2004.06.076</idno><idno type="wicri:Area/PubMed/Corpus">002C65</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.</title><author><name sortKey="He, Runtao" sort="He, Runtao" uniqKey="He R" first="Runtao" last="He">Runtao He</name><affiliation><nlm:affiliation>National Microbiology Laboratory, Health Canada, 1015 Arlington St., Winnipeg, MB, Canada R3E 3R2. runtao_he@hc-sc.gc.ca</nlm:affiliation></affiliation></author><author><name sortKey="Adonov, Anton" sort="Adonov, Anton" uniqKey="Adonov A" first="Anton" last="Adonov">Anton Adonov</name></author><author><name sortKey="Traykova Adonova, Maya" sort="Traykova Adonova, Maya" uniqKey="Traykova Adonova M" first="Maya" last="Traykova-Adonova">Maya Traykova-Adonova</name></author><author><name sortKey="Cao, Jingxin" sort="Cao, Jingxin" uniqKey="Cao J" first="Jingxin" last="Cao">Jingxin Cao</name></author><author><name sortKey="Cutts, Todd" sort="Cutts, Todd" uniqKey="Cutts T" first="Todd" last="Cutts">Todd Cutts</name></author><author><name sortKey="Grudesky, Elsie" sort="Grudesky, Elsie" uniqKey="Grudesky E" first="Elsie" last="Grudesky">Elsie Grudesky</name></author><author><name sortKey="Deschambaul, Yvon" sort="Deschambaul, Yvon" uniqKey="Deschambaul Y" first="Yvon" last="Deschambaul">Yvon Deschambaul</name></author><author><name sortKey="Berry, Jody" sort="Berry, Jody" uniqKey="Berry J" first="Jody" last="Berry">Jody Berry</name></author><author><name sortKey="Drebot, Michael" sort="Drebot, Michael" uniqKey="Drebot M" first="Michael" last="Drebot">Michael Drebot</name></author><author><name sortKey="Li, Xuguang" sort="Li, Xuguang" uniqKey="Li X" first="Xuguang" last="Li">Xuguang Li</name></author></analytic><series><title level="j">Biochemical and biophysical research communications</title><idno type="ISSN">0006-291X</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Aurintricarboxylic Acid (pharmacology)</term><term>Cell Division (drug effects)</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Reproducibility of Results</term><term>SARS Virus (drug effects)</term><term>SARS Virus (growth & development)</term><term>SARS Virus (ultrastructure)</term><term>Sensitivity and Specificity</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Aurintricarboxylic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Division</term><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Vero Cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs alpha and beta, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs alpha and beta, ATA was approximately 10 times more potent than IFN alpha and 100 times more than interferon beta at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15249217</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-291X</ISSN><JournalIssue CitedMedium="Print"><Volume>320</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month><Day>06</Day></PubDate></JournalIssue><Title>Biochemical and biophysical research communications</Title><ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation></Journal><ArticleTitle>Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.</ArticleTitle><Pagination><MedlinePgn>1199-203</MedlinePgn></Pagination><Abstract><AbstractText>The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being 1000-fold less than that in the untreated control. Importantly, when compared with IFNs alpha and beta, viral production was inhibited by more than 1000-fold as compared with the untreated control. In addition, when compared with IFNs alpha and beta, ATA was approximately 10 times more potent than IFN alpha and 100 times more than interferon beta at their highest concentrations reported in the literature previously. Our data indicated that ATA should be considered as a candidate anti-SARS compound for future clinical evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Runtao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Microbiology Laboratory, Health Canada, 1015 Arlington St., Winnipeg, MB, Canada R3E 3R2. runtao_he@hc-sc.gc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adonov</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Traykova-Adonova</LastName><ForeName>Maya</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cutts</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Grudesky</LastName><ForeName>Elsie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Deschambaul</LastName><ForeName>Yvon</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Jody</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Drebot</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuguang</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochem Biophys Res Commun</MedlineTA><NlmUniqueID>0372516</NlmUniqueID><ISSNLinking>0006-291X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4431-00-9</RegistryNumber><NameOfSubstance UI="D001312">Aurintricarboxylic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Biochem Biophys Res Commun. 2004 Nov 19;324(3):1152-3</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001312" MajorTopicYN="N">Aurintricarboxylic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth & development</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15249217</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2004.06.076</ArticleId><ArticleId IdType="pii">S0006291X04012240</ArticleId><ArticleId IdType="pmc">PMC7111066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Soc Exp Biol Med. 1972 Mar;139(3):811-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5023770</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Avian Pathol. 2003 Dec;32(6):567-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14676007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1976 Nov;75(1):155-65</Citation><ArticleIdList><ArticleId IdType="pubmed">824815</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Bacteriol. 1971 Mar;105(3):902-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5547994</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Neurochem. 1993 Jul;61(1):378-81</Citation><ArticleIdList><ArticleId IdType="pubmed">8515286</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Nov 28;311(4):870-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14623261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Apr;10(4):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15200845</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 1979 Jun;9(6):722-8</Citation><ArticleIdList><ArticleId IdType="pubmed">500803</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Apr 2;316(2):476-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15020242</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S6-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15018126</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1986 Apr 14;136(1):64-71</Citation><ArticleIdList><ArticleId IdType="pubmed">3010977</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Apr;10(4):368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15034574</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Pharmacol. 1984 Apr 1;33(7):1047-57</Citation><ArticleIdList><ArticleId IdType="pubmed">6324811</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1971 Jan;68(1):97-101</Citation><ArticleIdList><ArticleId IdType="pubmed">5276307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1992 May 29;185(1):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1599491</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 1983 Oct 25;11(20):7031-42</Citation><ArticleIdList><ArticleId IdType="pubmed">6314272</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002C65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15249217
|texte= Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15249217" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |